13.26
前日終値:
$12.81
開ける:
$13.11
24時間の取引高:
3.00M
Relative Volume:
0.65
時価総額:
$1.57B
収益:
$67.67M
当期純損益:
$-412.69M
株価収益率:
-3.4652
EPS:
-3.8266
ネットキャッシュフロー:
$-395.87M
1週間 パフォーマンス:
+0.38%
1か月 パフォーマンス:
-1.19%
6か月 パフォーマンス:
-20.17%
1年 パフォーマンス:
+51.89%
Intellia Therapeutics Inc Stock (NTLA) Company Profile
名前
Intellia Therapeutics Inc
セクター
電話
857-285-6200
住所
40 ERIE STREET, CAMBRIDGE, MA
Compare NTLA vs VRTX, REGN, ALNY, ARGX, INSM
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc
|
13.26 | 1.51B | 67.67M | -412.69M | -395.87M | -3.8266 |
|
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
|
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Intellia Therapeutics Inc Stock (NTLA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-02 | アップグレード | William Blair | Mkt Perform → Outperform |
| 2025-11-12 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
| 2025-11-11 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2025-11-07 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2025-10-28 | ダウングレード | Bernstein | Outperform → Mkt Perform |
| 2025-10-28 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-10-27 | ダウングレード | Guggenheim | Buy → Neutral |
| 2025-10-27 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2025-10-06 | アップグレード | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2025-04-21 | アップグレード | Wolfe Research | Peer Perform → Outperform |
| 2025-03-05 | 開始されました | H.C. Wainwright | Buy |
| 2025-02-28 | ダウングレード | Goldman | Neutral → Sell |
| 2025-02-28 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2025-01-27 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2024-02-23 | ダウングレード | Goldman | Buy → Neutral |
| 2024-02-15 | 開始されました | Wolfe Research | Peer Perform |
| 2023-04-13 | 開始されました | Canaccord Genuity | Buy |
| 2023-03-21 | 開始されました | Bernstein | Outperform |
| 2023-03-14 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2023-02-01 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-01-24 | アップグレード | Citigroup | Sell → Neutral |
| 2023-01-19 | ダウングレード | JMP Securities | Mkt Outperform → Mkt Perform |
| 2022-10-11 | 開始されました | Morgan Stanley | Overweight |
| 2022-09-21 | 開始されました | JP Morgan | Overweight |
| 2022-09-01 | 開始されました | Citigroup | Sell |
| 2022-06-17 | 開始されました | BMO Capital Markets | Market Perform |
| 2022-06-16 | 開始されました | BofA Securities | Buy |
| 2022-04-28 | 開始されました | Credit Suisse | Outperform |
| 2022-02-18 | 開始されました | William Blair | Outperform |
| 2022-02-07 | アップグレード | Oppenheimer | Perform → Outperform |
| 2022-01-31 | 開始されました | Cowen | Outperform |
| 2022-01-07 | 開始されました | Piper Sandler | Overweight |
| 2021-10-05 | 開始されました | Guggenheim | Buy |
| 2021-09-24 | 開始されました | Stifel | Buy |
| 2021-06-28 | 繰り返されました | H.C. Wainwright | Buy |
| 2021-06-11 | 開始されました | H.C. Wainwright | Buy |
| 2021-05-07 | アップグレード | ROTH Capital | Neutral → Buy |
| 2021-05-04 | 開始されました | RBC Capital Mkts | Outperform |
| 2021-03-04 | 開始されました | JMP Securities | Mkt Outperform |
| 2020-12-22 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2020-10-27 | 開始されました | Truist | Buy |
| 2020-10-14 | 開始されました | Wells Fargo | Overweight |
| 2020-09-18 | 開始されました | Goldman | Buy |
| 2020-02-28 | アップグレード | Oppenheimer | Perform → Outperform |
| 2020-02-14 | ダウングレード | Wedbush | Outperform → Neutral |
| 2019-11-01 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2019-07-09 | 開始されました | Robert W. Baird | Outperform |
| 2019-06-10 | 開始されました | ROTH Capital | Neutral |
| 2019-05-03 | アップグレード | Wedbush | Neutral → Outperform |
| 2019-04-12 | 開始されました | Evercore ISI | Outperform |
| 2018-11-02 | ダウングレード | Wedbush | Outperform → Neutral |
| 2018-10-29 | 開始されました | Credit Suisse | Neutral |
| 2018-09-21 | 開始されました | Raymond James | Mkt Perform |
| 2018-05-15 | アップグレード | Chardan Capital Markets | Neutral → Buy |
| 2018-03-08 | 開始されました | JMP Securities | Mkt Outperform |
| 2017-11-01 | 繰り返されました | Jefferies | Buy |
| 2017-06-22 | 再開されました | Jefferies | Buy |
| 2017-03-28 | 開始されました | Chardan Capital Markets | Buy |
| 2016-08-05 | アップグレード | Jefferies | Hold → Buy |
すべてを表示
Intellia Therapeutics Inc (NTLA) 最新ニュース
Risk Hedge: Is Intellia Therapeutics Inc a top pick in the sectorQuarterly Market Summary & Reliable Momentum Entry Alerts - baoquankhu1.vn
Investors in Intellia Therapeutics, Inc. Should Contact Levi & Ko - The National Law Review
Aug Drivers: Does Intellia Therapeutics Inc have a sustainable dividendQuarterly Growth Report & Smart Swing Trading Alerts - baoquankhu1.vn
Hudson Bay Capital Management LP Sells 235,000 Shares of Intellia Therapeutics, Inc. $NTLA - MarketBeat
NTLA SEC FilingsIntellia Therape 10-K, 10-Q, 8-K Forms - Stock Titan
Intellia rises on Q4 earnings & revenue beat, focuses on pipeline - MSN
Intellia jumps as FDA lifts clinical hold on Nex-Z for ATTR-CM - MSN
How Intellia Therapeutics Inc. (NTLA) Affects Rotational Strategy Timing - Stock Traders Daily
Intellia Therapeutics’ stock rocked by patient death in gene therapy trial - MSN
Intellia Therapeutics (NTLA) Soars to New High as Analysts Trigger ‘Buy’ - MSN
NTLA Technical Analysis | Trend, Signals & Chart Patterns | INTELLIA THERAPEUTICS INC (NASDAQ:NTLA) - ChartMill
Best CRISPR Companies for 2026 and How to Invest in Them - The Motley Fool
Intellia Therapeutics, Inc. $NTLA Position Trimmed by Granahan Investment Management LLC - MarketBeat
Farallon Capital Management LLC Purchases Shares of 607,200 Intellia Therapeutics, Inc. $NTLA - MarketBeat
KalVista Pharmaceuticals: Has Potential But With Caveats (NASDAQ:KALV) - Seeking Alpha
Lost Money on Intellia Therapeutics, Inc.(NTLA)? Join Class Acti - GuruFocus
Is Intellia Therapeutics (NTLA) Turning Regulatory Scrutiny Into a Strategic Edge in Gene Editing? - Sahm
Intellia Therapeutics at Leerink Global Healthcare Conference: Gene Editing Prospects - Investing.com Canada
Intellia Therapeutics: Why The Clinical Hold Lift Isn't A Total Victory (NASDAQ:NTLA) - Seeking Alpha
NTLA: Mid-year Phase 3 data could enable a first-in-class, one-time gene editing launch for HAE - TradingView
(NTLA) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Cathie Wood's Intellia Therapeutics Surges 47%: Is It Too Late to Invest? - Intellectia AI
This Cathie Wood Stock Is Up 47% This Year: Is It Too Late to Buy? - Nasdaq
Assessing Intellia Therapeutics (NTLA) Valuation After FDA Hold Lift And New Gene Editing Data - Sahm
Intellia Therapeutics (NASDAQ:NTLA) Upgraded at Wall Street Zen - MarketBeat
Intellia Therapeutics Q4 2025 earnings preview - MSN
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
CRISPR firm Intellia hands 16,500 RSUs to six new hires - Stock Titan
Cathie Wood’s ARK Made Just One Buy Last Session — And It’s A Biotech Stock Up Nearly 30% YTD - Stocktwits
Analysts Offer Insights on Healthcare Companies: Rigel (RIGL), Arcturus Therapeutics (ARCT) and Intellia Therapeutics (NTLA) - The Globe and Mail
Is Intellia Therapeutics (NTLA) Pricing Look Interesting After Strong Year-To-Date Share Gain? - simplywall.st
A Look At Intellia Therapeutics (NTLA) Valuation After Its Recent Share Price Rebound - Yahoo Finance
Amova Asset Management Americas Inc. Cuts Position in Intellia Therapeutics, Inc. $NTLA - MarketBeat
ARK Investment Management LLC Trims Stake in Intellia Therapeutics, Inc. $NTLA - MarketBeat
Jones Trading Upgrades Intellia Therapeutics (NTLA) - Nasdaq
FDA again targets GLP-1 compounders; Intellia to restart heart disease trial - BioPharma Dive
Intellia Therapeutics (NASDAQ:NTLA) Upgraded at JonesTrading - MarketBeat
This Target Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Wednesday - Benzinga
NTLA Stock Upgrade: Jones Trading Raises Intellia Therapeutics t - GuruFocus
HC Wainwright Has Pessimistic Outlook of NTLA Q1 Earnings - MarketBeat
Brookline Capital Maintains Buy on Intellia Therapeutics Inc (NTLA) March 2026 - Meyka
Wells Fargo Raises Price Target for Intellia Therapeutics (NTLA) to $15 | NTLA Stock News - GuruFocus
Intellia (NTLA) CEO John M. Leonard awarded large option and RSU grants - Stock Titan
Intellia (NTLA) EVP receives stock awards and small tax-driven share sale - Stock Titan
Intellia Therapeutics (NTLA) CMO awarded options and RSUs in Form 4 filing - Stock Titan
Intellia Therapeutics (NTLA) CFO granted stock options and RSUs - Stock Titan
Intellia Therapeutics (NTLA) CSO awarded options and RSUs - Stock Titan
Intellia Therapeutics (NTLA) EVP gets stock awards and sells shares for taxes - Stock Titan
Intellia Therapeutics (NTLA) CAO awarded 17,250 restricted stock units - Stock Titan
Intellia Therapeutics (NASDAQ:NTLA) Given New $48.00 Price Target at Canaccord Genuity Group - MarketBeat
Intellia Therapeutics Inc (NTLA) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):